Contribute Try STAT+ Today

Bristol-Myers Squibb, fighting off investor protests of its planned merger with Celgene, has won over the most influential advisers on Wall Street, improving the company’s odds of pulling off the $74 billion deal.

ISS and Glass Lewis, two powerful investment advisory services, endorsed the proposed deal Friday, siding with Bristol-Myers over dissident shareholders who argue that Celgene is too risky to justify the acquisition price. The firms’ coveted blessing comes weeks before the April 12 shareholder vote that will decide whether Bristol-Myers gets its way.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.